Don't Increase the Trazodone Dose—Consider Switching to a Different Agent
You should not be using trazodone for insomnia in the first place, and if you've already started it, 1-2 weeks is sufficient to determine if there's any subjective benefit before discontinuing it. The 2019 VA/DoD guidelines explicitly advise against using trazodone for chronic insomnia disorder 1, and the 2017 American Academy of Sleep Medicine guidelines recommend that clinicians NOT use trazodone for sleep onset or sleep maintenance insomnia 2.
Why Trazodone Should Not Be Your Go-To Agent
The evidence base for trazodone is remarkably weak:
- No objective sleep improvements: Systematic reviews found no differences in sleep efficiency, sleep onset latency, total sleep time, or wake after sleep onset compared to placebo 1
- Only subjective benefit: Trazodone showed improvement only in subjective sleep quality, not in any objective polysomnographic measures 1
- Very short study durations: The evidence comes from studies with mean treatment duration of only 1.7 weeks and follow-up of just 1-4 weeks 1
- Low-quality evidence: The guideline panels concluded that the adverse effect profile outweighs the minimal efficacy data 1
Timeline for Assessment
If you've already started trazodone despite guideline recommendations:
- Evaluate at 1-2 weeks: Based on the FDA labeling, the dose can be increased every 3-4 days for depression 3, but for insomnia, subjective sleep quality improvements (the only benefit shown) should be apparent within the first week based on study data 4, 5
- Maximum trial period: 4 weeks: This aligns with the longest follow-up periods in the systematic reviews 1 and represents a reasonable outer limit for assessing any potential benefit
- Don't escalate doses beyond 50-100 mg for insomnia: Higher doses increase adverse effects without established additional benefit for sleep 1, 4
What You Should Do Instead
Switch to evidence-based alternatives rather than increasing trazodone:
First-Line Treatment
- Cognitive Behavioral Therapy for Insomnia (CBT-I): This is the recommended first-line treatment 1, 6
Pharmacologic Options (if CBT-I unavailable or unsuccessful)
Consider these agents with actual evidence support:
- Low-dose doxepin (3-6 mg): Improves sleep efficiency, total sleep time, and sleep quality with better evidence 1
- Nonbenzodiazepine BZRAs (zolpidem, eszopiclone, zaleplon): Improve multiple sleep parameters including sleep efficiency, onset latency, and total sleep time 1
- Ramelteon (8 mg): For sleep onset difficulties 2
Critical Adverse Effects to Monitor
If continuing trazodone despite recommendations, watch for:
- Cognitive impairment: Short-term memory and verbal learning deficits occur even at 50 mg doses 4
- Motor impairment: Equilibrium problems and muscle endurance reduction 4
- Daytime drowsiness: Significantly more common than placebo 7
- Cardiovascular effects: Hypotension, QT prolongation risk 3
- Priapism: Rare but serious adverse effect requiring immediate discontinuation 3
Common Pitfalls to Avoid
Don't keep escalating the dose hoping for better results: The evidence doesn't support dose-response efficacy for insomnia, and adverse effects increase with higher doses 1, 4
Don't continue indefinitely without reassessment: If there's no subjective improvement by 2-4 weeks, discontinue and switch to an evidence-based agent 1, 6
Don't use trazodone as a "safe" alternative to other hypnotics: It has its own significant adverse effect profile including cognitive impairment, falls risk, and cardiovascular effects 1, 4
Don't ignore the 2008 guideline's placement of trazodone: Even older guidelines placed trazodone as a third-line option after BZRAs and only when treating comorbid depression 8
The bottom line: If you're not seeing clear subjective sleep improvement within 1-2 weeks on trazodone 50-100 mg, stop it and transition to an evidence-based alternative rather than increasing the dose. Better yet, don't start trazodone for insomnia at all given the strong guideline recommendations against its use 1, 2.